Shares of Orchard Therapeutics fell in trading after the company announced a new strategic plan that includes the shift in clinical focus, the shuttering of a proposed manufacturing facility in California and the termination of 25 percent of company staff.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
W2O announced a partnership with New Mountain Capital to accelerate continued growth and scale of the company to meet the evolving needs of its clients to most effectively and efficiently communicate with and influence their key stakeholders in an increasingly digital and mobile world.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
AbbVie announced a new executive leadership team structure designed to streamline the company’s organizational structure and support its long-term growth strategy.
Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.
Don’t fall under the digital bus. That’s how Gartner’s 2016 report characterizes the certainty and velocity of the movement to digital. And, according to IDC, two-thirds of CEOs plan to focus on digital transformation strategies in 2016. No doubt that many life sciences company CEOs will be among those on the digital bus.
